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Abstract
Chloroquine is a 4-aminoquinoline previously used in malaria therapy and now becoming an
emerging investigational antiviral drug due to its broad spectrum of antiviral activities. To explore
whether the low pH-dependency of influenza A viruses might affect the antiviral effects of
chloroquine at clinically achievable concentrations, we tested the antiviral effects of this drug on
selected human and avian viruses belonging to different subtypes and displaying different pH
requirements. Results showed a correlation between the responses to chloroquine and NH4Cl, a
lysosomotropic agent known to increase the pH of intracellular vesicles. Time-of-addition
experiments showed that the inhibitory effect of chloroquine was maximal when the drug had been
added at the time of infection and was lost after 2 h post-infection. This timing approximately
corresponds to that of virus/cell fusion. Moreover, there was a clear correlation between the EC50
of chloroquine in vitro and the electrostatic potential of the HA subunit (HA2) mediating the virus/
cell fusion process. Overall, the present study highlights the critical importance of a host cell factor
such as intravesicular pH in determining the anti-influenza activity of chloroquine and other
lysosomotropic agents.
Background
A second look at selected compounds is giving new life to
several abandoned therapies and new applications for
existing drugs [1-3]. One such example is provided by
chloroquine, being dismissed from antimalarial treat-
ment and finding new applications in the clinical man-
agement of autoimmune diseases, tumours and non-
malarial infections [4,5]. The use of chloroquine in the
clinical management of a viral infection was first consid-
ered in the 1990s, on the basis of its effects on HIV-1 [6,7].
The drug is now being tested as an investigational antiret-
roviral [8].
Some of us previously analysed the reported effects of
chloroquine on replication of several viruses and con-
cluded that the drug should be studied as a broad spec-
trum antiviral agent against emerging viral infections,
being relatively well tolerated, cheap, and immediately
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available worldwide [9]. As a weak base capable of accu-
mulating within cellular organelles, chloroquine appears
to be capable of interfering with pH-dependent steps in
the replication of several viruses. Other mechanisms of
viral inhibition by chloroquine, such as inhibition of
polynucleotidyl transferases have, however, been consid-
ered [7]. In 2003–2005, chloroquine was studied as a
promising  in vitro anti-SARS agent [9-11] and recently
entered clinical trials against chikungunya fever [12].
The broad-spectrum antiviral effects of chloroquine
deserve particular attention in a time in which there are
several cases of avian influenza A virus transmission to
humans from poultry, and the availability of antiviral
drugs is fundamental during preparation and evaluation
of effective vaccines. Chloroquine inhibition of both type
A and B influenza viruses was first described in the 1980s
[13,14]. The concentrations employed in these studies
were however too high to allow a theoretical transposition
to in-vivo settings. Anecdotal reports of clinical benefits
derived from a related compound, i.e. quinine, date back
to the Spanish influenza pandemic of 1918/19. However,
it was not until last year that the anti-influenza virus
effects of chloroquine at clinically achievable concentra-
tions were studied, in view of a possible application of
this drug in the clinical management of influenza [4,15].
Investigations still have to be done on this topic. For
example, the mechanisms of orthomyxovirus inhibition
by chloroquine have been uncertain at the clinically
achievable concentrations adopted in the most recent
studies [4,15], as well as the effects of chloroquine on field
isolates, including avian strains potentially transmittable
to humans.
We here report the results of an initial evaluation of sus-
ceptibility to chloroquine of human and avian influenza
A viruses. Susceptibility to chloroquine appears to be
dependent on the pH requirements of the viruses and the
electrostatic potential of haemagglutinin subunit 2
(HA2), which is involved in virus/cell fusion. Accordingly,
the antiviral effects are exerted at an early step of virus rep-
lication.
Results
We first tested the effects of chloroquine on low-patho-
genic (LP) A/Ck/It/9097/97 (H5N9) virus, isolated from
poultry in Italy. We found that chloroquine dose-depend-
ently inhibited the viral cytopathic effect with a 50% effec-
tive concentration (EC50) of 14.38 μM, in cells infected
with the H5N9 virus at approx. 104 50% tissue culture
infecting doses (TCID50)/ml (Fig. 1a). Although this value
was rather high, some of the inhibitory concentrations
matched the blood concentrations reported in individuals
under acute antimalarial treatment (1–15 μM). The inhib-
itory effects were confirmed using quantitative reverse
transcritptase real-time PCR (qRRT-PCR) (Fig. 1b).
Ooi et al. (2006) [15] recently reported that chloroquine
inhibited human H3N2 and H1N1 viruses with EC50 val-
ues in the range of 0.84 – 3.60 μM. To investigate whether
the discrepancies with the inhibitory values reported
above were due to the type of virus or to the different con-
ditions and methods adopted, we tested the effects of
chloroquine on replication of recent human H3N2 and
H1N1 viral isolates under conditions similar to those
adopted for the H5N9 avian influenza virus. Using the test
of inhibition of viral cytopathogenicity, we found that
chloroquine inhibited the H3N2 virus (10 4 TCID50/ml)
with an EC50 of 1.53 μM (Fig.1c). Inhibition was con-
firmed using qRRT-PCR, both under similar conditions
and at lower MOIs (Fig.1d), thus confirming the results of
Ooi et al. (the assay adopted by these authors employs a
lower MOI than routinely used by our group). Results
obtained with H1N1 viruses (104 TCID50/ml) showed a
similar drug susceptibility for the human strain (EC50 =
1.26 μM), in full agreement with Ooi et al. [15], but no
response to clinically achievable drug concentrations in
an avian strain (IC50 > 20 μM; data not shown). These data
suggest a more pronounced inhibitory effect of chloro-
quine on human H3N2 and H1N1 viruses than on avian
H5N9 virus replication.
Since 1) chloroquine is thought to interfere with pH-
dependent steps of the life cycles of several viruses [9], and
2) some of us reported different pH requirements in influ-
enza A viruses infecting different avian species [15], we
investigated whether response of influenza viruses to
chloroquine might depend on the different pH require-
ments of the human and avian viruses.
Thus, we analysed the response of human H3N2 virus
(good chloroquine responder) and avian H5N9 virus
(poor chloroquine responder) to ammonium chloride
(NH4Cl; 40 mM), a lysosomotropic agent known to
increase the pH of intracellular vesicles. Results showed a
good response of the chloroquine-sensitive H3N2 virus to
NH4Cl inhibition of viral cytopathogenicity (100% inhi-
bition under conditions described above). Conversely,
the lower chloroquine-sensitivity of H5N9 virus was asso-
ciated with lack of response to NH4Cl (data not shown).
This observation raised the hypothesis that cellular pH
might be a critical factor for chloroquine inhibition of
influenza virus.
To explore this possibility, the action of chloroquine was
tested on two avian H7N3 viruses whose haemagglutinins
(HAs) differ in two amino acid positions (i.e. residue 261
in the HA1 subunit and residue 161 in HA2, the latter
being the HA subunit mediating the fusion process), andVirology Journal 2007, 4:39 http://www.virologyj.com/content/4/1/39
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which display different pH requirements [16]. The two
viral strains showed a marked discrepancy in the response
to chloroquine. In particular, A/Mallard/It/43/01 (H7N3)
virus, which had been shown to be relatively more inde-
pendent from pH increase than A/Ty/It/220158/02 virus
[16], was insensitive to clinically achievable chloroquine
concentrations (EC50 > 20 μM). In contrast, chloroquine
exerted some inhibitory effect on A/Ty/It/220158/02 rep-
lication (EC50 = 14.39 μM), although the response of this
virus to chloroquine was lower than that of H3N2 virus.
The different pH requirements of the two viruses were
confirmed by the different responses to NH4Cl (0% inhi-
bition for A/Mallard/It/43/01; 30% inhibition for A/Ty/It/
220158/02). This result raises the hypothesis that chloro-
quine inhibits pH-dependent events involving HA.
To further explore this possibility, the isoelectric point
was calculated for HAs of all viruses used in the present
study, and the electrostatic potential was mapped on the
protein surfaces of 3D models obtained by homology
Inhibition of H5 and H3 influenza A virus replication by CQ in MDCK cells Figure 1
Inhibition of H5 and H3 influenza A virus replication by CQ in MDCK cells. Cells were incubated with chloroquine 
(CQ) after virus inoculation or mock-infection and tested for cell viability and viral RNA copies at 24 h post-infection. A) Via-
bility of cells infected with A/Chicken/Italy/9097/97 (H5N9) and treated with increasing concentrations of CQ as detected by 
colorimetric test. Assays were performed as described in the text. The dotted line indicates inhibition of uninfected cell viabil-
ity, the solid line indicates inhibition of infected cell viability. Results are presented as the curves that best fit the data points. B) 
Results of one representative experiment showing inhibition by CQ of A/Chicken/Italy/9097/97 viral RNA production. Virus 
infected MDCK cells were incubated for one day in the presence of 0, 5, 10, 20 or 25 μM chloroquine. Cell supernatants were 
used for viral RNA extraction and subjected to a quantitative real-time RT-PCR (qRRT-PCR) assay. Oseltamivir (OS; 20 nM) 
was used as a positive control. C and D) as in A and B), respectively, using A/Panama/2007/99-like (H3N2) virus. In D) both 
results obtained with inocula containing 104 and 103 TCID50/ml are reported. Results in B) and D) are displayed for purely rep-
resentative reasons to show that there is inhibition of virus production, and cannot be compared with each other or with 
those in A) and C), due to the high intra- and inter-assay variability of the qRRT PCR assay (see Ref. [29]).
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with the crystal structures of matched subtype representa-
tives. Results showed a negative correlation between the
isoelectric point of HA2 and the IC50 of chloroquine in
vitro (r = -0.87; P = 0.024; Fig. 2). Instead, no correlation
was found with the isoelectric point of HA1 (P > 0.05;
data not shown). Although the viruses studied here
belonged to different subtypes, chloroquine-resistant
viruses, independently of the subtype, showed a more
marked negative surface potential of HA2 than chloro-
quine-sensitive viruses (Fig. 2). Viruses with intermediate
drug sensitivity showed intermediate characteristics (Fig.
2). We conclude that structural determinants in HA2 are
associated with response of influenza A viruses to chloro-
quine.
If the hypothesis of a pH dependent inhibitory action of
chloroquine was correct, the timing of drug inhibition
should match that of virus/cell fusion, an early step of
virus replication occurring in endosomes and requiring a
low pH (approx. pH 5–5.5) in several, but not all, influ-
enza A viruses, as shown by previous studies [17]. As the
assays for detection of antiviral effects adopted in the first
Correlation between electric characteristics of haemagglutinin subunit 2 (HA2) and response to chloroquine of influenza A  viruses Figure 2
Correlation between electric characteristics of haemagglutinin subunit 2 (HA2) and response to chloroquine 
of influenza A viruses. A) Correlation between EC50 of chloroquine (CQ) on viral cytopathogenicity (presented as Log val-
ues, x axis) and isoelectric point of HA2 (pH value at which the protein is neutral; y axis). The line best fitting the data points is 
shown. Isoelectric points were calculated based on the protein sequence using the web interface in Ref. [35]. B-G) Theoretical 
three-dimensional models for HA2 subunits of the viruses adopted in the present study, shown in ranked order of sensitivity to 
chloroquine (from resistant to clinically achievable concentrations to fully sensitive). B) A/Mallard/Italy/43/01 (H7N3); C); A/
Mallard/Italy/66/96 (H1N1); D) A/Chicken/Italy/9097/97 (H5N9); E) A/Turkey/Italy/220158/02 (H7N3); F) Human influenza A/
Panama/2007/99-like (H3N2); G) A/New Caledonia/20/99-like (H1N1). The electrostatic potential is mapped to the protein 
surface as a range of colours from red (-1.8 V) to blue (+1.8 V). Equipotential surfaces are shown as dotted line grids. Protein 
sequence data regarding the H7N3 and H5N9 viruses can be found in GenBank with the following accession numbers: 
AAT37405, AAT37404, AAG60349.
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part of this study were designed to allow multiple cycles
of viral replication, we designed time-of-addition experi-
ments using the chloroquine-sensitive human H3N2
virus. Chloroquine was added during virus adsorption
onto cells (i.e. time 0; T0) and/or at 1, 2, 3 and 4 h post-
infection (T1–4) Using qRRT-PCR, we found that the
inhibitory effect of chloroquine was highest when the
drug was added at T0 (inhibition of viral replication corre-
sponding to 89,36%) and at T1 (inhibition of replication
corresponding to 15,53%), whereas the inhibitory activity
was completely lost at T2.
If this timing was correct, chloroquine should inhibit
influenza A replication by a novel mechanism, and there-
fore exert additive effects in combination with oseltami-
vir, inhibiting neuraminidase activity at the late stages of
viral replication cycle. To test this hypothesis, human
H3N2 virus-infected cells were treated with different chlo-
roquine concentrations in the presence or absence of osel-
tamivir (10 nM). The virus-infected cells were also
incubated with oseltamivir alone, EC50= 20 nM. Isobolo-
gram analysis showed that the two drugs exerted an addi-
tive effect (sum of FICs = 1) (data not shown). This result
provides further evidence that chloroquine inhibits viral
replication by a mechanism different from that of one
major anti-influenza drug.
Discussion
The results so far obtained suggest that chloroquine inhib-
its the replication of those influenza A viruses requiring
low pH for proper fusion activation and that the antiviral
effects occur at an early stage of viral replication. Support-
ing evidence comes from: 1) the more sustained inhibi-
tory effect of chloroquine on those viruses whose
haemagglutinins (HAs) were found to require low pH for
their fusion activity, 2) common HA2 characteristics such
as surface potential and isoelectric point in chloroquine-
sensitive viruses, and 3) time-of-addition experiments
with H3N2 virus.
Chloroquine was found to inhibit a number of cellular
processes, some of which do not depend on low pH but
might anyway interfere with viral replication. For exam-
ple, the drug was found to inhibit viral nucleotidyl trans-
ferases such as HIV-1 integrase [7]. If chloroquine
inhibited influenza A RNA-dependent RNA polymerase,
the timing of viral inhibition would not be consistent
with that observed in the present study, because RNA rep-
lication occurs in the nucleus at later stages [18].
Based on bioinformatic studies, it was recently hypothe-
sized that chloroquine might inhibit UDP- N acetylglu-
cosamine transferase [1], a limiting enzyme in sialic acid
synthesis. This specific issue has not been addressed here.
Nonetheless, if the antiviral effect of chloroquine reported
here were due to inhibition of UDP-N acetylglucosamine
transferase, the drug should likely have antagonized the
antiviral effect of the neuraminidase inhibitor oseltamivir
(acting on detachment of sialic acid-bound virions from
parent cells), rendering oseltamivir inhibition unneces-
sary. Instead, chloroquine was found in the present study
to exert antiviral effects that were additive to those of osel-
tamivir.
Chloroquine is a weak base that is known to affect acid
vesicles leading to dysfunction of several proteins [9], and
has been shown to inhibit different viruses requiring a
pH-dependent step for entry [19-22]. The results of the
time-of-addition experiments, performed in the present
study using a recent epidemic isolate of human H3N2
virus, are consistent with chloroquine inhibition of pH-
dependent steps occurring at an early phase of influenza A
virus replication.
Most influenza viruses enter target cells by fusion of the
viral and cell membranes at the endosomal pH (approx.
pH 5–5.5), although some virus variants can replicate well
also at higher pH values [16,17,23]. In a previous paper,
the differential growth sensitivity of two naturally occur-
ring variants of an H7N3 virus, isolated from mallards
and turkeys, to increased pH values was shown to corre-
late with different fusion properties [16]. Since chloro-
quine appears to mimic the effects observed on these two
viruses when pH is increased, our data support the
hypothesis that the step of virus replication inhibited by
clinically relevant chloroquine concentrations is the low-
pH dependent haemagglutinin-mediated virus/cell
fusion, in agreement with the evidence obtained by other
authors at much higher concentrations than those used in
this study [13,14]. The correspondence between antiviral
effects and isoelectric point of HA2 (i.e. the HA subunit
mediating the fusion process) is also consistent with this
mechanism. Acidic pH in the endosomal compartment
also activates the influenza virus ion channel, M2, that
promotes the uncoating of influenza virus in endosomes.
However, M2 involvement as a possible target of the anti-
viral effect of chloroquine is unlikely, since no aminoacid
differences were observed in M2 trans-membrane region
(the ion-channel domain) between the two avian H7N3
viruses with different chloroquine sensitivities, as already
reported [16].
Although a comprehensive study on the variation of
fusion pH requirements of influenza A viruses of all HA
subtypes and isolates from different hosts is not available,
several authors have documented that the threshold pH,
at which the HA conformational change and virus-cell
fusion occur, is strain-specific [24-26]. Interestingly, the
viruses showing highest chloroquine sensitivity also dis-
played the highest HA2 isoelectric points. Thus, a relation-Virology Journal 2007, 4:39 http://www.virologyj.com/content/4/1/39
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ship between isoelectric point and response to pH is
apparent. However, a broad study relating the surface
electrostatic potential with inactivation by pH would be
required to analyse the molecular details of the HA/pH
interplay. Analyses of virus production before and after
exposure to chloroquine and of the possible changes in
HA2 surface potential in viruses rendered resistant to
chloroquine after long exposure to the drug will also be
necessary.
Conclusion
Although association between variables cannot be consid-
ered to be equivalent to causation, the results of the
present study strongly suggest that pH critically deter-
mines the antiviral activity of chloroquine by regulating
virus/host cell interactions. The potential use of this com-
pound as an antiinfluenza drug should take into consid-
eration the possibility that even within the same subtype,
different strains may present significantly divergent sensi-
tivities to chloroquine as a consequence of their different
pH requirements. Moreover, sensitivity to chloroquine
may vary in different cell populations susceptible to influ-
enza A virus infection, depending on different capabilities
of endosome acidification. Mutations affecting the elec-
trostatic potential of the the HA2 protein subunit of vari-
ous isolates of the same virus could also be relevant. All
these factors should be carefully evaluated when hypoth-
esising a potential clinical utilisation of chloroquine
against influenza A viruses.
Materials and methods
Cells and virus stocks
Madin Darby Canine Kidney (MDCK) cells were obtained
from the American Type Culture Collection. The follow-
ing viruses were used in this study: two recent human
strains, A/Panama/2007/99-like (H3N2) and A/New Cal-
edonia/20/99-like (H1N1), and four LP avian influenza
viruses, A/Chicken/Italy/9097/97 (H5N9), A/Turkey/
Italy/220158/02 (H7N3) and A/Mallard/Italy/43/01
(H7N3), A/Mallard/Italy/66/96 (H1N1). Virus titration
was performed by 50% tissue culture infectious dose
(TCID50) in MDCK cells, as described [27], and virus
stocks were aliquoted and stored at -70°C until used. All
the viruses were from the Istituto Superiore di Sanità (ISS)
repository. Virus infection of MDCK cell monolayers was
carried out according to standard procedures [28].
Compounds
Chloroquine phosphate (7-chloro-4- [4-(diethylamino)-
1-methylbutyl]amino]quinoline phosphate, (Sigma) and
oseltamivir, a kind gift from Roche was used as a positive
control.
Virus yield assay
After 24 hours of incubation of the virus-infected cells
with different concentrations of the test compounds,
under the appropriate conditions, pooled aliquots of the
supernatants containing free viruses were subjected to
RNA extraction and qRRT-PCR.
Quantitative Real Time RT-PCR (qRRT-PCR)
A one-step qRRT-PCR assay was employed, which makes
use of minor groove binder (MGB) probe technology, as
previously described [29]. Briefly, viral RNA was extracted
from infected cell supernatants (QIAmp Viral RNA Mini
kit – Qiagen, GmbH, Hilden, Germany) and amplified by
RRT-PCR using primers and probe targeting a highly con-
served region of the matrix gene of influenza type A
viruses. The influenza matrix RNA was also in vitro tran-
scribed from the corresponding DNA template, cloned
into a plasmid vector as previously described [29] and
used as standard RNA to generate standard curves for
quantification of the vRNA in cell supernatants.
Assay for measurement of antiviral activity
100  μl of 1.5 × 105  cells/ml MDCK cells in growth
medium was seeded into each well in the 96-well micro-
titer plate. When the cell monolayer was confluent, the
culture medium was removed and cells were washed twice
with serum-free MEM. Then, 100 μl of the Type A influ-
enza viruses under study containing 103 – 104 TCID50 were
inoculated in wells and the plates incubated for 1 hour at
37°C in humidified air of 5% CO2. The viral suspension
was removed and the cells were washed two times; fresh
medium containing TPCK-trypsin and chloroquine at dif-
ferent concentrations or NH4Cl (40 mM) was then added
to culture wells in triplicate. Antiviral activity and cytotox-
icity measurements were based on the viability of cells
that had been infected or mock infected with influenza
viruses in the presence of various concentrations of the
test compounds. One to three days, depending on the
kinetics of cytopathogenicity, after infection the number
of viable cells was quantified by a tetrazolium-salt-based-
colorimetric method (CellTiter 96 AQueous One Solution
kit, Promega, The Netherlands).
Assessment of the effects of two drugs in combination
To measure the anti-influenza effects of chloroquine/osel-
tamivir drug combinations, cell pellets were resuspended
in media containing increasing concentrations of the anti-
malarial in the presence or absence of oseltamivir. A frac-
tional inhibitory concentration (FIC) was then calculated
as the ratio: 50% effective concentration (EC50) of drug A
in combination with drug B/EC50 of drug A alone. The
effect was considered to be additive when the sum of FICs
was between 0.8 and 1.2, as previously described [8]Virology Journal 2007, 4:39 http://www.virologyj.com/content/4/1/39
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Time-of-addition assay
Monolayers of MDCK cells in 96-well plates were infected
with 100 μl of medium containing approximately 104
TCID50 of H3N2 subtype. After 1 hour of adsorption, cell
monolayers were washed twice with serum-free MEM and
incubated in fresh medium containing TPCK-trypsin and
chloroquine at a concentration of 10 μM. Chloroquine
was added at the time of infection or at four different time
points thereafter. Eight hours post-infection, a time point
at which all progeny virus in the supernatants is derived
from the first replication cycle, cell supernatants were col-
lected, viral RNA was extracted and the antiviral activity
was determined by using the qRRT-PCR described above.
Viral RNA sequencing
Hemagglutinin genes of H3N2 and H1N1 viruses were
sequenced using gene-specific primers, as previously
described [30]. Sequence data so far unpublished will be
deposited in GenBank by the time of publication of the
present article.
Molecular modelling
Three-dimensional models for the HAs of the viruses used
in the present study were obtained by homology model-
ling, using the SWISS model web server [31,32], using, as
templates, structures of matched subtype representatives
deposited in the protein data bank (PDB) [33]. Hydro-
gens were added using VEGA-ZZ (University of Milan,
Italy) [34], and the structures were then visualised using
the Swiss PDB Viewer (SPDBV) program (Swiss Institute
of Bioinformatics) [31].
The Coulomb potential was mapped to the protein sur-
face by use of SPDBV using the default relative dielectric
constant (solvent = water) of 80. Further information on
the algorithm adopted by the program is available in the
detailed online description of the program [31].
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